SCHEMBL24525035

SCHEMBL24525035

COC(=O)c1cc(I)c(-c2ccc(F)c(Cl)c2)cc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.50
ABL1 P00519 1/20 0.49
MAPT P10636 4/20 0.41
CASP3 P42574 2/20 0.41
SENP7 Q9BQF6 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 4/20 0.41
GAA P10253 3/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
CASP1 P29466 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
GLA P06280 1/20 0.40
CASP7 P55210 1/20 0.40
ATM Q13315 1/20 0.40
FYN P06241 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29654654 1.00 CFTR (0.50) CFTRABL1MAPTCASP3SENP7
SCHEMBL24525040 0.88 ABL1 (0.49) CFTRABL1MAPTCASP3SENP7
SCHEMBL29654580 0.84 CFTR (0.55) CFTRABL1MAPTCASP3SENP7
SCHEMBL24525042 0.84 CFTR (0.55) CFTRABL1MAPTCASP3SENP7
SCHEMBL29476340 0.84 CFTR (0.51) CFTRABL1MAPTCASP3SENP7
SCHEMBL23540452 0.84 CFTR (0.51) CFTRABL1MAPTCASP3SENP7
SCHEMBL29654682 0.83 ABL1 (0.63) CFTRABL1MAPTCASP3SENP7
SCHEMBL23540082 0.83 SLC6A4 (0.56) CFTRABL1MAPTCASP3SENP7
SCHEMBL24524941 0.83 ABL1 (0.63) CFTRABL1MAPTCASP3SENP7
SCHEMBL29476152 0.83 SLC6A4 (0.56) CFTRABL1MAPTCASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845761-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2023-12-19 US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 US disclosed
US-20230107642-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-04-06 US disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 WO disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107642-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS CFTR 1205/4885ABL1 111/4885MAPT 4642/4885
US-11845761-B2 Tricyclic pyridones and pyrimidones KRAS, NRAS, HRAS CFTR 1205/4885ABL1 111/4885MAPT 4642/4885
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS CFTR 1205/4885ABL1 111/4885MAPT 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.